StopUMTS Logo
how to get rid of moles 
Zoeken
   
Voorlichting
06/11/17Beschermen tegen de ra
12/10/17Meetspecialisten, meet
Artikelen
18/11/17Vuile stroom (netvervuili
16/11/17ADHD is meer een probleem
16/11/17Mobile phones cause letha
16/11/17Mt Nardi Wildlife Report
15/11/17Cell Phone Headaches –
14/11/1715.000 wetenschappers uit
Berichten Nederland
18/11/17KWF collecteert met stral
16/11/17Promotie van een psycholo
16/11/17Toename van klachten in N
14/11/17Aantal antenne-installati
13/11/17Vanavond 13 nov. in Radar
Berichten België
14/11/17Hoe gezond of ongezond is
24/10/17NMBS-baas Sophie Dutordoi
Berichten Internationaal
18/11/17IARC-WHO: Global burden o
18/11/17Duits verbod op 'slimme'
14/11/17De stralingsbelasting en
09/11/17Bill Gates and Steve Jobs
Ervaringen | Appellen/oproepen
17/11/17Alice kan niet tegen stra
12/11/17Afscherming, voor sommige
05/11/17TV met WiFi; een ervaring
Onderzoeken
14/11/17Modeled and Perceived Exp
06/11/17Decreases in sleep durati
25/10/17Radiation from wireless t
Veel gestelde vragen
13/05/17Vakantie? Witte zo
10/07/16Zeven veel gestelde vrage
Juridische informatie
08/11/17InPower Movement: Early r
19/10/17The precautionary princip
11/10/17Telekom warns of (its own
Oproepen
29/11/17Raadsmarkt ZENDMASTEN &
11/11/17Cursus ‘Straling meten
29/10/17Petitie: Geen uitbreiding
Folders
10/09/17Brochures, folders, websi
29/04/16USA: Meer dan 50 tips voo
Briefwisselingen | Archief: 2008, 2005
10/07/17Brief naar de gemeente C.
14/06/17Mail naar 'De Monitor' na
Illustraties
 Algemeen
 Fotoalbum zendmasten
 Wetenschappelijke illustraties
USA/Frankrijk/Brazilië: Zwakke EMV blijken effectief bij de behandeling van o.a. levertumoren.    
Ga naar overzicht berichten in: Onderzoeken

USA/Frankrijk/Brazilië: Zwakke EMV blijken effectief bij de behandeling van o.a. levertumoren.
zondag, 04 december 2011 - Dossier: Algemeen


Zwakke EMV met specifieke frequentiemodulaties blijken effectief bij de behandeling van levertumoren, eierstokkanker en borstkanker bij veldsterkten ver beneden de op warmte-effecten gebaseerde normen. De onderzoekers hebben geen bio-fysische verklaring voor de effecten, het werkingsmechanisme is onbekend:

Bron: British Medical Journal 9 aug. 2011 en 1 dec 2011

Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields

F P Costa1, A C de Oliveira1, R Meirelles1, M C C Machado1, T Zanesco1, R Surjan1, M C Chammas2, M de Souza Rocha2, D Morgan3, A Cantor4, J Zimmerman5, I Brezovich6, N Kuster7, A Barbault8 and B Pasche5

1 Department of Transplantation and Liver Surgery, Hospital das Clínicas da Faculdade de Medicina, University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar, 255, São Paulo 05403-000, Brazil

2 Department of Radiology, Hospital das Clínicas, University of São Paulo, São Paulo 05403-000, Brazil

3 Department of Radiology, University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL 35294, USA

4 Biostatistics and Bioinformatics Shared Facility, University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL 35294, USA

5 Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham and UAB Comprehensive Cancer Center, 1802 6th Ave South, NP 2566, Birmingham, AL 35294-3300, USA

6 Department of Radiation Oncology, The University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL 35294, USA

7 IT'IS Foundation, Swiss Federal Institute of Technology, Zurich, Switzerland
8Rue de Verdun 20, Colmar 68000, France

Correspondence:
Dr FP Costa, E-mail: fredericoperegocosta@gmail.com;
Dr B Pasche, E-mail: Boris.Pasche@ccc.uab.edu

Therapeutic options for patients with advanced hepatocellular carcinoma (HCC) are limited. There is emerging evidence that the growth of cancer cells may be altered by very low levels of electromagnetic fields modulated at specific frequencies.

Methods:

A single-group, open-label, phase I/II study was performed to assess the safety and effectiveness of the intrabuccal administration of very low levels of electromagnetic fields amplitude modulated at HCC-specific frequencies in 41 patients with advanced HCC and limited therapeutic options. Three-daily 60-min outpatient treatments were administered until disease progression or death. Imaging studies were performed every 8 weeks. The primary efficacy end point was progression-free survival greater than or equal to6 months. Secondary efficacy end points were progression-free survival and overall survival.

Results:

Treatment was well tolerated and there were no NCI grade 2, 3 or 4 toxicities. In all, 14 patients (34.1%) had stable disease for more than 6 months. Median progression-free survival was 4.4 months (95% CI 2.1–5.3) and median overall survival was 6.7 months (95% CI 3.0–10.2). There were three partial and one near complete responses.

Conclusion:

Treatment with intrabuccally administered amplitude-modulated electromagnetic fields is safe, well tolerated, and shows evidence of antitumour effects in patients with advanced HCC.

Voor het originele abstract zie:
www.nature.com/bjc/journal/v105/n5/abs/bjc2011292a.html .

en voor de sceptici zie het follow-up paper van 1 dec 2011:
www.nature.com/bjc/journal/vaop/ncurrent/abs/bjc2011523a.html .

Voor een deskundig Engelstalig commentaar bij deze verbazingwekkende ontdekking zie:
www.microwavenews.com/ModulationFrequencies.html .


Ga terug naar het hoofdmenu
Afdrukken | Vragen | RSS | Disclaimer